Aptahem reports delay in delivery of its drug product
Aptahem (publ) announced today that manufacture of its drug product has been delayed as a result of technical challenges. As a consequence, Aptahem anticipates that commencement of the planned clinical study for Apta-1 will be delayed.
Aptahem reports that the delivery of its drug product will be delayed. A need to have more drug product manufactured was announced in a press release on August 28, 2018 during the preclinical toxicology program. Aptahem has learned that the delay is due to a series of technical difficulties that have been encountered during the contract manufacturer’s production.
The contract manufacturer is working on solutions and concurrent with these activities, Aptahem is considering alternative options to limit the delay. Aptahem will publicly announce more details as soon as a new timeline and appreciation of costs have been made.
“Today’s announcement is unfortunate; I am disappointed that we will not be able to deliver on our communicated time line, but I am confident we will find a solution that will bring us to our next stage of development as quickly as possible,” commented Mikael Lindstam, CEO of Aptahem.
As a consequence of today’s announcement, the planned clinical study will not start during the third quarter this year as previously communicated.
For further information:
Mikael Lindstam, CEO
Tel: 0766-33 36 99
This information is information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on February 8, 2019.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.